Potential Therapeutic Role of Budesonide to Reduce COVID-19 Severity

Overview

Journal J Infect Public Health

Publisher Elsevier

Specialties Infectious Diseases
Public Health

Date 2021 Nov 22

PMID 34802976

Authors

Md Mohiuddin

Kazuo Kasahara

Affiliations

Soon will be listed here.

References

Yu L, Bafadhel M, Dorward J, Hayward G, Saville B, Gbinigie O . Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021; 398(10303):843-855. PMC: 8354567. DOI: 10.1016/S0140-6736(21)01744-X. View

Petrocheilou A, Tanou K, Kalampouka E, Malakasioti G, Giannios C, Kaditis A . Viral croup: diagnosis and a treatment algorithm. Pediatr Pulmonol. 2014; 49(5):421-9. DOI: 10.1002/ppul.22993. View

Ramakrishnan S, Nicolau Jr D, Langford B, Mahdi M, Jeffers H, Mwasuku C . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021; 9(7):763-772. PMC: 8040526. DOI: 10.1016/S2213-2600(21)00160-0. View

Pavord I, Holliday M, Reddel H, Braithwaite I, Ebmeier S, Hancox R . Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med. 2020; 8(7):671-680. DOI: 10.1016/S2213-2600(20)30053-9. View

Kothe T, Royse E, Kemp M, Schmidt A, Salomone F, Saito M . Effects of budesonide and surfactant in preterm fetal sheep. Am J Physiol Lung Cell Mol Physiol. 2018; 315(2):L193-L201. PMC: 6139660. DOI: 10.1152/ajplung.00528.2017. View

Finney L, Glanville N, Farne H, Aniscenko J, Fenwick P, Kemp S . Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol. 2020; 147(2):510-519.e5. PMC: 7558236. DOI: 10.1016/j.jaci.2020.09.034. View

Hashemian S, Mortaz E, Jamaati H, Bagheri L, Mohajerani S, Garssen J . Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients: Association with inflammatory mediators and cells. J Crit Care. 2017; 44:161-167. DOI: 10.1016/j.jcrc.2017.10.045. View

Shuto H, Komiya K, Yamasue M, Uchida S, Ogura T, Mukae H . A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Sci Rep. 2020; 10(1):20935. PMC: 7708623. DOI: 10.1038/s41598-020-78054-2. View

Yeh T, Chen C, Wu S, Husan Z, Li T, Hsieh W . Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2015; 193(1):86-95. DOI: 10.1164/rccm.201505-0861OC. View

10.

Daher A, Balfanz P, Aetou M, Hartmann B, Muller-Wieland D, Muller T . Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. Sci Rep. 2021; 11(1):2256. PMC: 7838409. DOI: 10.1038/s41598-021-81444-9. View

11.

Sharma A, Tiwari S, Deb M, Marty J . Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020; 56(2):106054. PMC: 7286265. DOI: 10.1016/j.ijantimicag.2020.106054. View

12.

Agusti A, Torres F, Faner R . Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. Lancet Respir Med. 2021; 9(7):682-683. PMC: 8040539. DOI: 10.1016/S2213-2600(21)00171-5. View

13.

Venkataraman R, Kamaluddeen M, Hasan S, Robertson H, Lodha A . Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis. Pediatr Pulmonol. 2017; 52(7):968-975. DOI: 10.1002/ppul.23680. View

14.

OConnell E . Efficacy of budesonide in moderate to severe asthma. Clin Ther. 2002; 24(6):887-905; discussion 837. DOI: 10.1016/s0149-2918(02)80005-4. View

15.

Bassler D, Plavka R, Shinwell E, Hallman M, Jarreau P, Carnielli V . Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med. 2015; 373(16):1497-506. DOI: 10.1056/NEJMoa1501917. View

16.

Tashkin D, Strange C . Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?. Int J Chron Obstruct Pulmon Dis. 2018; 13:2587-2601. PMC: 6118265. DOI: 10.2147/COPD.S172240. View

17.

Pan J, Chen M, Ni W, Fang T, Zhang H, Chen Y . [Clinical efficacy of pulmonary surfactant combined with budesonide for preventing bronchopulmonary dysplasia in very low birth weight infants]. Zhongguo Dang Dai Er Ke Za Zhi. 2017; 19(2):137-141. PMC: 7389465. View

18.

Bao W, Chen Q, Lin Y, Liu H, Zhao G, Chen Z . Efficacy of procaterol combined with inhaled budesonide for treatment of cough-variant asthma. Respirology. 2013; 18 Suppl 3:53-61. DOI: 10.1111/resp.12169. View

19.

Kothe T, Kemp M, Schmidt A, Royse E, Salomone F, Clarke M . Surfactant plus budesonide decreases lung and systemic inflammation in mechanically ventilated preterm sheep. Am J Physiol Lung Cell Mol Physiol. 2019; 316(5):L888-L893. PMC: 6589588. DOI: 10.1152/ajplung.00477.2018. View

20.

Selroos O, Lofroos A, Pietinalho A, NIEMISTO M, Riska H . Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis. 1994; 11(2):126-31. View